Partners

 
 
About the Multiple Myeloma Research Foundation®
 
The mission of the Multiple Myeloma Research Foundation (MMRF) is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and find a cure. Founded in 1998 by multiple myeloma patient Kathy Giusti and her twin sister Karen Andrews as a 501(c)(3) non-profit organization, the MMRF is a world-recognized leader in cancer research. Together with its partners, the MMRF created the only end-to-end solution in precision medicine, generated the single largest genomic data set in all cancers and continues to disrupt, pioneer and lead new research efforts. The MMRF has raised over $400 million since its inception and directs nearly 90% of the total funds raised to research and related programs. For more information, visit mmrf.org.
 
About Multiple Myeloma
 
Multiple myeloma is a type of blood cancer that affects the plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow, crowding out the normal plasma cells that help fight infections. These malignant plasma cells then produce abnormal proteins (m protein), which may cause tumors, damage the kidneys, and impair immune system function. 

Multiple myeloma is the second most common blood cancer, and although it is considered incurable, it is very much a treatable disease thanks to recent advancements in cancer research. Historically, there was little hope for multiple myeloma patients, because multiple myeloma treatment options were incredibly limited. The Multiple Myeloma Research Foundation (MMRF), however, has revolutionized the way multiple myeloma is treated, substantially improving the life expectancy of multiple myeloma patients. Since its inception, the MMRF has helped introduce ten new drugs and through the power of new technology, genomics, and immunology, lives are now being saved.
 
 
ABOUT CURE®
 
CURE Media Group’s flagship product, CURE magazine, is the indispensable guide to every stage of the cancer experience. With nearly 1 million readers, CURE is the largest consumer publication in the United States focused entirely on cancer, with broad distribution to cancer patients, cancer centers and advocacy groups. CURE Media Group’s offerings also include its online resource, curetoday.com; live meetings; a resource guide for the newly diagnosed; and the Extraordinary Healer™ national nursing award. CURE Media Group combines science and humanity to make cancer understandable.
 
 
SUPPORTING SPONSORS
 
 
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com
 
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
With a focus on delivering transformational therapies for cancer patients GSK’s pipeline  includes immuno-oncology, cell therapy, and epigenetics. Our goal is to achieve a sustainable flow of new treatments for cancer patients based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, multi-specific molecules, adjuvants and cells, either alone or in combination.
Company values are Patient focus, Transparency, Respect and Integrity.
 
bristol myers squibb logo
 
Bristol Myers Squibb is inspired by a single vision–transforming patients' lives through science. The goal of the company's cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine, and through innovative digital platforms, are turning data into insights that sharpen their focus. Deep scientific expertise, cutting-edge capabilities and discovery platforms enable the company to look at cancer from every angle. Cancer can have a relentless grasp on many parts of a patient's life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship. Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.
 
sanofi logo
 
Sanofi Genzyme is the specialty care global business unit of Sanofi. We strive to help people with complex conditions that may be difficult to treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com.
oncopeptides logo
 
At Oncopeptides we are committed to the development of therapies for difficult-to-treat hematological diseases. We strive to bring hope to patients through science and innovation. Every day we are inspired by the perseverance that we see from patients, care givers and health care providers in their fight against cancer. We are unwavering in our focus and dedication to bring forward new and meaningful treatment options. Find out more at https://www.oncopeptides-us.com/en.
Interested in multiple myeloma updates from CURE®? Sign up for our newsletter!

Partners
Multiple Myeloma Research Foundation

View our interviews with climber Chuck Wakefield
Terms & Conditions | Privacy Policy